Build Your Comparison

Side-by-side financial analysis
NYXH logo
NYXH
INSP logo
INSP
LIVN logo
LIVN
KO logo
KO
Try popular comparisons:

Stock Comparison

NYXH vs INSP vs LIVN vs KO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NYXH
Nyxoah S.A.

Medical - Instruments & Supplies

HealthcareNASDAQ • BE
Market Cap$52M
5Y Perf.-94.2%
INSP
Inspire Medical Systems, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$1.23B
5Y Perf.-82.0%
LIVN
LivaNova PLC

Medical - Devices

HealthcareNASDAQ • GB
Market Cap$4.36B
5Y Perf.-6.5%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+53.1%

NYXH vs INSP vs LIVN vs KO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NYXH logoNYXH
INSP logoINSP
LIVN logoLIVN
KO logoKO
IndustryMedical - Instruments & SuppliesMedical - DevicesMedical - DevicesBeverages - Non-Alcoholic
Market Cap$52M$1.23B$4.36B$355.61B
Revenue (TTM)$16M$915M$1.43B$49.28B
Net Income (TTM)$-86M$131M$107M$13.70B
Gross Margin48.3%85.8%67.5%61.7%
Operating Margin-5.3%5.6%13.4%29.3%
Forward P/E47.6x18.7x25.3x
Total Debt$42M$32M$473M$45.49B
Cash & Equiv.$30M$105M$636M$10.27B

NYXH vs INSP vs LIVN vs KOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NYXH
INSP
LIVN
KO
StockApr 21Jun 26Return
Nyxoah S.A. (NYXH)1005.8-94.2%
Inspire Medical Sys… (INSP)10018.0-82.0%
LivaNova PLC (LIVN)10093.5-6.5%
The Coca-Cola Compa… (KO)100153.1+53.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: NYXH vs INSP vs LIVN vs KO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: INSP and LIVN are tied at the top with 2 categories each — the right choice depends on your priorities. LivaNova PLC is the stronger pick specifically for valuation and capital efficiency and recent price momentum and sentiment. KO and NYXH also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
NYXH
Nyxoah S.A.
The Growth Play

NYXH is the clearest fit if your priority is growth exposure.

  • Rev growth 121.6%, EPS growth -30.9%, 3Y rev CAGR 48.1%
  • 121.6% revenue growth vs KO's 1.9%
Best for: growth exposure
INSP
Inspire Medical Systems, Inc.
The Income Pick

INSP has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.

  • Dividend streak 0 yrs, beta 1.16
  • Lower volatility, beta 1.16, Low D/E 4.1%, current ratio 6.08x
  • Beta 1.16, current ratio 6.08x
  • Beta 1.16 vs NYXH's 2.10, lower leverage
Best for: income & stability and sleep-well-at-night
LIVN
LivaNova PLC
The Value Play

LIVN is the #2 pick in this set and the best alternative if value and momentum is your priority.

  • Lower P/E (18.7x vs 25.3x)
  • +70.3% vs NYXH's -81.6%
Best for: value and momentum
KO
The Coca-Cola Company
The Long-Run Compounder

KO is the clearest fit if your priority is long-term compounding.

  • 121.1% 10Y total return vs INSP's 70.9%
  • 27.8% margin vs NYXH's -5.3%
  • 2.5% yield; 56-year raise streak; the other 3 pay no meaningful dividend
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthNYXH logoNYXH121.6% revenue growth vs KO's 1.9%
ValueLIVN logoLIVNLower P/E (18.7x vs 25.3x)
Quality / MarginsKO logoKO27.8% margin vs NYXH's -5.3%
Stability / SafetyINSP logoINSPBeta 1.16 vs NYXH's 2.10, lower leverage
DividendsKO logoKO2.5% yield; 56-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)LIVN logoLIVN+70.3% vs NYXH's -81.6%
Efficiency (ROA)INSP logoINSP15.2% ROA vs NYXH's -80.8%, ROIC 6.0% vs -76.4%

NYXH vs INSP vs LIVN vs KO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

NYXHNyxoah S.A.

Segment breakdown not available.

INSPInspire Medical Systems, Inc.
FY 2025
Operating Segment
100.0%$912M
LIVNLivaNova PLC
FY 2025
Cardiopulmonary Segment
57.0%$785M
Neuromodulation Segment
43.0%$593M
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B

NYXH vs INSP vs LIVN vs KO — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLIVNLAGGINGNYXH

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 3 of 6 comparable metrics.

KO is the larger business by revenue, generating $49.3B annually — 3020.2x NYXH's $16M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to NYXH's -5.3%. On growth, NYXH holds the edge at +5.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…LIVN logoLIVNLivaNova PLCKO logoKOThe Coca-Cola Com…
RevenueTrailing 12 months$16M$915M$1.4B$49.3B
EBITDAEarnings before interest/tax-$81M$62M$220M$15.5B
Net IncomeAfter-tax profit-$86M$131M$107M$13.7B
Free Cash FlowCash after capex-$73M$97M$161M$12.6B
Gross MarginGross profit ÷ Revenue+48.3%+85.8%+67.5%+61.7%
Operating MarginEBIT ÷ Revenue-5.3%+5.6%+13.4%+29.3%
Net MarginNet income ÷ Revenue-5.3%+14.3%+7.5%+27.8%
FCF MarginFCF ÷ Revenue-4.5%+10.6%+11.2%+25.5%
Rev. Growth (YoY)Latest quarter vs prior year+5.9%+1.6%+14.3%+12.1%
EPS Growth (YoY)Latest quarter vs prior year+38.3%-5.0%+106.7%+18.2%
KO leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

LIVN leads this category, winning 3 of 6 comparable metrics.

At 8.7x trailing earnings, INSP trades at a 68% valuation discount to KO's 27.2x P/E. On an enterprise value basis, LIVN's 17.4x EV/EBITDA is more attractive than KO's 26.4x.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…LIVN logoLIVNLivaNova PLCKO logoKOThe Coca-Cola Com…
Market CapShares × price$52M$1.2B$4.4B$355.6B
Enterprise ValueMkt cap + debt − cash$66M$1.2B$4.2B$390.8B
Trailing P/EPrice ÷ TTM EPS-0.51x8.73x-17.84x27.18x
Forward P/EPrice ÷ next-FY EPS est.47.59x18.68x25.27x
PEG RatioP/E ÷ EPS growth rate2.43x
EV / EBITDAEnterprise value multiple17.83x17.39x26.39x
Price / SalesMarket cap ÷ Revenue4.48x1.35x3.14x7.42x
Price / BookPrice ÷ Book value/share0.93x1.63x3.61x10.40x
Price / FCFMarket cap ÷ FCF15.68x25.18x67.15x
LIVN leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

INSP leads this category, winning 5 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-164 for NYXH. INSP carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), INSP scores 7/9 vs NYXH's 2/9, reflecting strong financial health.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…LIVN logoLIVNLivaNova PLCKO logoKOThe Coca-Cola Com…
ROE (TTM)Return on equity-164.4%+18.0%+9.1%+41.1%
ROA (TTM)Return on assets-80.8%+15.2%+4.2%+13.1%
ROICReturn on invested capital-76.4%+6.0%+11.5%+15.8%
ROCEReturn on capital employed-80.4%+6.7%+10.2%+17.3%
Piotroski ScoreFundamental quality 0–92757
Debt / EquityFinancial leverage0.86x0.04x0.39x1.33x
Net DebtTotal debt minus cash$12M-$73M-$162M$35.2B
Cash & Equiv.Liquid assets$30M$105M$636M$10.3B
Total DebtShort + long-term debt$42M$32M$473M$45.5B
Interest CoverageEBIT ÷ Interest expense-32.73x418.58x5.18x10.70x
INSP leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LIVN leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $515 for NYXH. Over the past 12 months, LIVN leads with a +70.3% total return vs NYXH's -81.6%. The 3-year compound annual growth rate (CAGR) favors LIVN at 18.3% vs INSP's -48.0% — a key indicator of consistent wealth creation.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…LIVN logoLIVNLivaNova PLCKO logoKOThe Coca-Cola Com…
YTD ReturnYear-to-date-69.1%-53.7%+30.9%+20.3%
1-Year ReturnPast 12 months-81.6%-66.8%+70.3%+17.2%
3-Year ReturnCumulative with dividends-82.4%-85.9%+65.4%+47.0%
5-Year ReturnCumulative with dividends-94.9%-77.3%-2.8%+65.6%
10-Year ReturnCumulative with dividends-94.2%+70.9%+62.7%+121.1%
CAGR (3Y)Annualised 3-year return-44.0%-48.0%+18.3%+13.7%
LIVN leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LIVN and KO each lead in 1 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than NYXH's 2.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIVN currently trades 98.3% from its 52-week high vs NYXH's 16.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…LIVN logoLIVNLivaNova PLCKO logoKOThe Coca-Cola Com…
Beta (5Y)Sensitivity to S&P 5002.10x1.16x1.23x-0.20x
52-Week HighHighest price in past year$8.59$147.03$80.73$84.04
52-Week LowLowest price in past year$1.26$38.91$41.02$65.35
% of 52W HighCurrent price vs 52-week peak+16.2%+29.0%+98.3%+98.3%
RSI (14)Momentum oscillator 0–10025.843.369.460.6
Avg Volume (50D)Average daily shares traded189K950K727K12.7M
Evenly matched — LIVN and KO each lead in 1 of 2 comparable metrics.

Analyst Outlook

KO leads this category, winning 1 of 1 comparable metric.

Analyst consensus: NYXH as "Buy", INSP as "Hold", LIVN as "Buy", KO as "Buy". Consensus price targets imply 331.7% upside for NYXH (target: $6) vs -0.2% for LIVN (target: $79). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…LIVN logoLIVNLivaNova PLCKO logoKOThe Coca-Cola Com…
Analyst RatingConsensus buy/hold/sellBuyHoldBuyBuy
Price TargetConsensus 12-month target$6.00$57.36$79.25$86.13
# AnalystsCovering analysts5271448
Dividend YieldAnnual dividend ÷ price+2.5%
Dividend StreakConsecutive years of raises056
Dividend / ShareAnnual DPS$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%+14.2%+0.1%+0.2%
KO leads this category, winning 1 of 1 comparable metric.
Key Takeaway

KO leads in 2 of 6 categories (Income & Cash Flow, Analyst Outlook). LIVN leads in 2 (Valuation Metrics, Total Returns). 1 tied.

Best OverallLivaNova PLC (LIVN)Leads 2 of 6 categories
Loading custom metrics...

NYXH vs INSP vs LIVN vs KO: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NYXH or INSP or LIVN or KO a better buy right now?

For growth investors, Nyxoah S.

A. (NYXH) is the stronger pick with 121. 6% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). Inspire Medical Systems, Inc. (INSP) offers the better valuation at 8. 7x trailing P/E (47. 6x forward), making it the more compelling value choice. Analysts rate Nyxoah S. A. (NYXH) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NYXH or INSP or LIVN or KO?

On trailing P/E, Inspire Medical Systems, Inc.

(INSP) is the cheapest at 8. 7x versus The Coca-Cola Company at 27. 2x. On forward P/E, LivaNova PLC is actually cheaper at 18. 7x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — NYXH or INSP or LIVN or KO?

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

6%, compared to -94. 9% for Nyxoah S. A. (NYXH). Over 10 years, the gap is even starker: KO returned +121. 1% versus NYXH's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NYXH or INSP or LIVN or KO?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Nyxoah S. A. 's 2. 10β — meaning NYXH is approximately -1147% more volatile than KO relative to the S&P 500. On balance sheet safety, Inspire Medical Systems, Inc. (INSP) carries a lower debt/equity ratio of 4% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — NYXH or INSP or LIVN or KO?

By revenue growth (latest reported year), Nyxoah S.

A. (NYXH) is pulling ahead at 121. 6% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: Inspire Medical Systems, Inc. grew EPS 179. 4% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, NYXH leads at 48. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NYXH or INSP or LIVN or KO?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -899. 1% for Nyxoah S. A. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -827. 8% for NYXH. At the gross margin level — before operating expenses — INSP leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NYXH or INSP or LIVN or KO more undervalued right now?

On forward earnings alone, LivaNova PLC (LIVN) trades at 18.

7x forward P/E versus 47. 6x for Inspire Medical Systems, Inc. — 28. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NYXH: 331. 7% to $6. 00.

08

Which pays a better dividend — NYXH or INSP or LIVN or KO?

In this comparison, KO (2.

5% yield) pays a dividend. NYXH, INSP, LIVN do not pay a meaningful dividend and should not be held primarily for income.

09

Is NYXH or INSP or LIVN or KO better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Nyxoah S. A. (NYXH) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, NYXH: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NYXH and INSP and LIVN and KO?

These companies operate in different sectors (NYXH (Healthcare) and INSP (Healthcare) and LIVN (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NYXH is a small-cap high-growth stock; INSP is a small-cap deep-value stock; LIVN is a small-cap quality compounder stock; KO is a large-cap quality compounder stock. KO pays a dividend while NYXH, INSP, LIVN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.